Overview

Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease

Status:
Unknown status
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether moxonidine is effective in reducing urine albumin levels in patients with diabetic kidney disease.
Phase:
Phase 4
Details
Lead Sponsor:
Baker Heart and Diabetes Institute
Baker IDI Heart and Diabetes Institute
Treatments:
Moxonidine